Education

The hub for all your learning resources.

Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.

90 minutes to Watch

This recorded webinar covers the introduction of the adalimumab biosimilar Amgevita in New Zealand, and what it means for primary care. Specialist Dr David Liew shares his experiences of changing patients from biologics to biosimilars in Australia, and Andrea Copeland provides some local context.

Contributor
Dr David Liew, Andrea Copeland
17 March 2022
1 minute to Read

Adalimumab is used to treat a range of dermatological, rheumatological, gastrointestinal and ophthalmologic conditions. From 1 March, Amgevita (an adalimumab biosimilar) is funded under Special Authority. From this date, patients starting treatment with adalimumab will receive Amgevita rather than the reference product, Humira. 

Contributor
He Ako Hiringa
1 March 2022
90 minutes to Watch

In this recorded webinar, Professor Lisa Stamp explores the management of gout as a long-term condition and challenges old beliefs. Dr Noni Richards introduces the EPiC Gout dashboard and outlines how it can be used to highlight and address inequities. 

Contributor
Professor Lisa Stamp, Dr Noni Richards
25 February 2022

Looking for up-to-date information on biological medicines? You can find it here!

We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need.

 

Contributor
He Ako Hiringa
14 February 2022
13 minutes to Read + 47 minutes to Delve

This article summarises the 2022 changes regarding adalimumab funding and access in New Zealand. It also provides some background and resources to foster confidence in biosimilars, and references real-world data from studies of patients changing from Humira to Amgevita.

Contributor
He Ako Hiringa
14 February 2022
1 minute to Read

Cardiovascular disease is the leading cause of death in New Zealand, accounting for 35 per cent of mortality in 2019. Yet it’s preventable and treatable. Māori, Pacific, and South Asian peoples have a disproportionately higher CVD risk compared with people not of these ethnicities. Therefore, CVD risk assessments in these ethnicities should begin earlier.

Contributor
He Ako Hiringa
28 January 2022
1 minute to Read

Prescribers are instrumental in framing a medicine positively or negatively, setting patient expectations. Optimising these expectations during a short consult can enhance and sustain benefits. Conversely, highlighting negative information may lead to increased experience, and reporting, of adverse events, and to poor adherence.

Contributor
He Ako Hiringa
26 November 2021
30 minutes to Listen

Episode three of our Legendary Conversations podcast is out now! Listen to three experts as they discuss attitudes towards gout and how to better communicate with patients to improve gout outcomes. 

Contributor
Professor Nicola Dalbeth, Carla White, Meihana Douglas
26 November 2021
10 minutes to Read + 2 minutes to Watch

Rosuvastatin is now fully funded on Special Authority for people at increased risk of cardiovascular complications due to high cholesterol, and may be considered first-line for Māori and Pacific peoples.

An abridged version of this article, containing the eligibility flowchart, is available for printing - see the link in the contents box. 

Contributor
He Ako Hiringa
15 November 2021